1. Home
  2. QTWO vs GPCR Comparison

QTWO vs GPCR Comparison

Compare QTWO & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QTWO

Q2 Holdings Inc.

HOLD

Current Price

$54.91

Market Cap

3.0B

Sector

Technology

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$48.96

Market Cap

2.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
QTWO
GPCR
Founded
2004
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.8B
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
QTWO
GPCR
Price
$54.91
$48.96
Analyst Decision
Buy
Strong Buy
Analyst Count
11
12
Target Price
$82.64
$103.17
AVG Volume (30 Days)
725.8K
808.9K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
225.00
N/A
EPS
0.40
N/A
Revenue
$193,978,000.00
N/A
Revenue This Year
$12.48
N/A
Revenue Next Year
$10.18
N/A
P/E Ratio
$138.73
N/A
Revenue Growth
N/A
N/A
52 Week Low
$40.79
$15.80
52 Week High
$92.66
$94.90

Technical Indicators

Market Signals
Indicator
QTWO
GPCR
Relative Strength Index (RSI) 65.04 50.39
Support Level $54.64 $42.72
Resistance Level $55.64 $57.15
Average True Range (ATR) 2.22 2.91
MACD 0.49 -0.92
Stochastic Oscillator 82.73 33.89

Price Performance

Historical Comparison
QTWO
GPCR

About QTWO Q2 Holdings Inc.

Q2 Holdings Inc provides digital solutions to financial institutions, financial technology companies, and alternative finance companies, seeking to incorporate banking into their customer engagement and servicing strategies. The company helps its clients with supervisory, consumer protection, privacy, third-party risk management requirements, and cyber threats and fraud, among other applications, by offering a portfolio of digital solutions, which comprises its digital banking offerings, digital lending and relationship pricing solutions, risk and fraud solutions, as well as Q2 Innovation Studio and Helix. Q2 derives the majority of its revenue from subscription fees for the use of its hosted solutions.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: